Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. - Wikidata - awgldk - TriplyDB

Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation.

Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation.

http://www.wikidata.org/entity/Q41144916

about

Dinosaurs and ancient civilizations: reflections on the treatment of cancer Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer.Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.The interconnectedness of cancer cell signaling.Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway.Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Protein trafficking in colorectal carcinogenesis-targeting and bypassing resistance to currently applied treatments.Selective β2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis.KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity.The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation.Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors

P2860

Q24628746-11D841E8-4E71-45FC-9EDA-BAB5BD49FFA1 Q33556731-1A88BD92-6A9F-429F-A0D8-2FA317B93C16 Q33618353-108151CA-3C76-4453-8CC0-7CD6F04CE2D8 Q34093266-48C805FF-926E-4BA2-B034-3D7DBE233313 Q35669733-F5D0E1F9-4541-4F85-B3A7-1D633534104C Q35882193-F24FE6EC-79AC-4A57-B626-D8D612048779 Q35933551-19674A5D-54AA-4604-888B-7658579C94A4 Q36335893-CB02EE20-A696-455C-A2C5-DFB03FC97C8B Q37720812-391F791F-A457-40E7-95A7-41E94F5E6009 Q38090584-48FF3B2D-AB29-4376-BB20-183D2CBA41D4 Q38166233-6F5FCB13-CEAB-4106-A3B1-0CC779FB4CA3 Q38415868-7AAF838A-CC86-4913-A50D-1300CEFC108C Q38851498-3153494B-64B0-400D-BA03-CCB40AC16278 Q39077167-1EC8C66B-4562-4010-B998-F98BFC648981 Q39236770-BBC03083-4A4D-4939-BB7F-7389510480CE Q41879186-FCE6A97B-EAA6-425D-93D0-FE0FF12C8D01 Q47391969-B5C78A1C-04AD-4A80-98EB-09C446733549 Q47817412-B9F140F4-7F4F-4B1F-9DA8-CE573E7090E1 Q54336425-AEADD38B-459B-454D-AC4D-DCF85FD187F6 Q58697094-48B690E9-5AA5-4C1C-BA5C-90BF04B4E8A5

P2860

Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation.

http://www.wikidata.org/entity/Q41144916

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Oncogenic KRAS desensitizes co ...... tor inhibition and activation.

@en

type

label

Oncogenic KRAS desensitizes co ...... tor inhibition and activation.

@en

prefLabel

Oncogenic KRAS desensitizes co ...... tor inhibition and activation.

@en

P1433

Q41144916-6C8838E0-D9D6-4791-8DA7-F2D1D6DE83D6

P1476

Q41144916-D151E824-9040-4712-874E-B8CCC1BA2A4D

P2093

Q41144916-036F1914-65DD-4AA9-8CC6-BE9D89F34DA1

Q41144916-0D03B2C0-9C5B-4951-B665-DB2E71D614E8

Q41144916-2B3F36FF-DFE9-4208-BA4C-9374013BD337

Q41144916-7E875AF9-FB30-45C5-AF60-5822ABA70D17

Q41144916-809C3FA6-7E3F-4A5F-BB31-CB5100F2C9DE

Q41144916-B5B89EF7-79A9-4DEE-A55F-81A174B3E44E

Q41144916-D3A022F3-392D-4735-9CC1-C219E8F264C0

Q41144916-ECE96991-6A7F-48B8-B65D-822A2C42F851

Q41144916-F26A3689-3770-46AC-AC43-6340E0078C9D

Q41144916-FEB3E785-B7E1-4B36-9ABC-5885D83F7779

P2860

Q41144916-074564D2-CBCE-4C03-AB7E-E865C543DAB4

Q41144916-18E68CAC-5049-4999-BB7E-FB17412910D7

Q41144916-1B1C528C-6BCC-435C-9E7B-30CAE1033904

Q41144916-2DDB14F4-62F1-4131-840B-94D54A7062B3

Q41144916-30F76C5F-25CC-402E-A8D1-4EF6752E8993

Q41144916-3B879AA8-B769-4013-BBA9-C17F51BB23AA

Q41144916-44FBD009-BB12-4B0B-AF75-C888BAAAF7AC

Q41144916-4681176F-2F93-4E2C-A0BF-653FB9AA043F

Q41144916-7A4CAF40-B847-47F6-858E-036818E8DB49

Q41144916-7C95184B-C2ED-4F27-86E0-E69EA1B1E417

P304

Q41144916-319E04EF-D979-4662-B587-29682A478B1F

P31

Q41144916-AB9F7625-E338-4276-A0CC-A7323E7FD23B

P356

Q41144916-65356939-D813-4DC6-9141-7D0D9C0CF9D7

P433

Q41144916-11F6865F-9BDC-44D6-9515-EADF0D023601

P478

Q41144916-75E6DFDE-9A75-4A69-B365-6A4C9E2E20D8

P577

Q41144916-12B8960E-0CBC-4F8E-9769-AB2DCA2CF7B3

P5875

Q41144916-C6360370-CA5C-40B7-98D1-D53BFE396688

P698

Q41144916-3546A679-171F-4E90-90C1-867404543B6D

P932

Q41144916-F7233DA3-5EE7-4780-9D35-27E80CECB388

P356

P1433

P1476

Oncogenic KRAS desensitizes co ...... tor inhibition and activation.

@en

P2093

Benjamin L Emmink

http://www.w3.org/2001/XMLSchema#string

Danielle A E Raats

http://www.w3.org/2001/XMLSchema#string

Frederik J H Hoogwater

http://www.w3.org/2001/XMLSchema#string

Inne H M Borel Rinkes

http://www.w3.org/2001/XMLSchema#string

Maarten W Nijkamp

http://www.w3.org/2001/XMLSchema#string

Menno T de Bruijn

http://www.w3.org/2001/XMLSchema#string

Onno Kranenburg

http://www.w3.org/2001/XMLSchema#string

Paul van Diest

http://www.w3.org/2001/XMLSchema#string

Petra van der Groep

http://www.w3.org/2001/XMLSchema#string

Winan J van Houdt

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Lessons from hereditary colorectal cancer

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.

P304

443-452

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.92088

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44687839

http://www.w3.org/2001/XMLSchema#string

P698

20563247

http://www.w3.org/2001/XMLSchema#string

P932

2887497

http://www.w3.org/2001/XMLSchema#string